{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T19:09:25Z","timestamp":1774033765513,"version":"3.50.1"},"reference-count":24,"publisher":"American Society of Hematology","issue":"6","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,3,24]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>Nonrelapse mortality (NRM) in allogeneic haemopoietic stem cell transplantation (alloHSCT) is driven by acute graft-versus-host disease (aGVHD) and infection. The MAGIC algorithm probability (MAP) composite biomarker score is based on serum ST2 and REG3a levels at day (D)7 after transplantation and predicts aGVHD-related mortality. Although changes in MAP score predict aGVHD treatment response, their posttransplant predictive value and association with infection-related NRM (iNRM), independent of GVHD, are unclear. We evaluated the association of D0 to D21 MAP change (MAP\u0394) vs D7 MAP with 6-month NRM (6mNRM) and developed a risk stratification model using random forest analysis and recursive partitioning. We prospectively enrolled 101 adult alloHSCT recipients from 2022 to 2024. Serum was collected weekly from D0 to D21 to derive MAP\u0394. Associations with 6mNRM were assessed using generalized linear and random forest modeling. 6mNRM was 14.8%, with 80% (12\/15) of deaths attributed to infection without prior aGVHD. Both MAP\u0394 \u22650.055 and D7 MAP \u22650.16 were significantly associated with 6mNRM (P&amp;lt; .0001), with MAP\u0394 showing superior predictive accuracy (receiver operator characteristic area under the curve 0.934 vs 0.779). In multivariable analysis, MAP\u0394 (odds ratio, 45; 95% confidence interval, 10.6-318; P = .01), but not D7 MAP, was an independent predictor of 6mNRM. A classification tree incorporating MAP\u0394, D7 MAP, and age-adjusted comorbidity index stratified patients into low, intermediate, and high-risk groups. MAP\u0394 was a powerful, independent predictor of 6mNRM, which was driven by infection rather than aGVHD in this cohort. We propose a tool based on MAP\u0394 to assess iNRM, which may guide interventions and clinical trial design. Further validation in larger cohorts is warranted.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/bloodadvances.2025017621","type":"journal-article","created":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T17:05:58Z","timestamp":1768496758000},"page":"2054-2064","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":0,"title":["A biomarker risk assessment tool predicts infection-related mortality after allogeneic stem cell transplantation"],"prefix":"10.1182","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2880-6340","authenticated-orcid":false,"given":"Joanne Lay Cheng","family":"Tan","sequence":"first","affiliation":[{"name":"1Department of Clinical Haematology, The Alfred Hospital, Melbourne, VIC, Australia"},{"name":"2Australian Centre of Blood Diseases, School of Translational Medicine, Monash University, Melbourne, VIC, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tiffany","family":"Khong","sequence":"additional","affiliation":[{"name":"2Australian Centre of Blood Diseases, School of Translational Medicine, Monash University, Melbourne, VIC, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6498-6222","authenticated-orcid":false,"given":"Yu Jin","family":"Kim","sequence":"additional","affiliation":[{"name":"1Department of Clinical Haematology, The Alfred Hospital, Melbourne, VIC, Australia"},{"name":"2Australian Centre of Blood Diseases, School of Translational Medicine, Monash University, Melbourne, VIC, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8825-8625","authenticated-orcid":false,"given":"John","family":"Reynolds","sequence":"additional","affiliation":[{"name":"1Department of Clinical Haematology, The Alfred Hospital, Melbourne, VIC, Australia"},{"name":"2Australian Centre of Blood Diseases, School of Translational Medicine, Monash University, Melbourne, VIC, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1433-2239","authenticated-orcid":false,"given":"Rahul D.","family":"Barmanray","sequence":"additional","affiliation":[{"name":"3Department of Medicine, The Royal Melbourne Hospital, The University of Melbourne, Melbourne, VIC, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bradley","family":"Gardiner","sequence":"additional","affiliation":[{"name":"4Department of Infectious Diseases, Alfred Health, Melbourne, VIC, Australia"},{"name":"5Department of Infectious Diseases, School of Translational Medicine, Monash University, Melbourne, VIC, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Catherine Orla","family":"Morrissey","sequence":"additional","affiliation":[{"name":"4Department of Infectious Diseases, Alfred Health, Melbourne, VIC, Australia"},{"name":"5Department of Infectious Diseases, School of Translational Medicine, Monash University, Melbourne, VIC, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sridurga","family":"Mithraprabhu","sequence":"additional","affiliation":[{"name":"2Australian Centre of Blood Diseases, School of Translational Medicine, Monash University, Melbourne, VIC, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew","family":"Spencer","sequence":"additional","affiliation":[{"name":"1Department of Clinical Haematology, The Alfred Hospital, Melbourne, VIC, Australia"},{"name":"2Australian Centre of Blood Diseases, School of Translational Medicine, Monash University, Melbourne, VIC, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"234","published-online":{"date-parts":[[2026,3,16]]},"reference":[{"issue":"1","key":"2026032014063830400_bib1","first-page":"48.e1-48.e10","article-title":"Post-transplantation cyclophosphamide is associated with an increase in non-cytomegalovirus herpesvirus infections in patients with acute leukemia and myelodysplastic syndrome","volume":"28","author":"Singh","year":"2022","journal-title":"Transpl Cell Ther"},{"issue":"1","key":"2026032014063830400_bib2","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1038\/s41409-023-02131-z","article-title":"Post-transplantation cyclophosphamide is associated with increased bacterial infections","volume":"59","author":"Ustun","year":"2024","journal-title":"Bone Marrow Transpl"},{"issue":"23","key":"2026032014063830400_bib3","doi-asserted-by":"crossref","first-page":"3291","DOI":"10.1182\/blood.2020009362","article-title":"Posttransplant cyclophosphamide is associated with increased cytomegalovirus infection: a CIBMTR analysis","volume":"137","author":"Goldsmith","year":"2021","journal-title":"Blood"},{"key":"2026032014063830400_bib4","doi-asserted-by":"crossref","first-page":"2338","DOI":"10.3389\/fimmu.2019.02338","article-title":"ST2 and REG3\u03b1 as predictive biomarkers after haploidentical stem cell transplantation using post-transplantation high-dose cyclophosphamide","volume":"10","author":"Solan","year":"2019","journal-title":"Front Immunol"},{"issue":"2","key":"2026032014063830400_bib5","first-page":"97.e1-97.e6","article-title":"Pretransplantation plasma ST2 level as a prognostic biomarker of 1-year nonrelapse mortality in allogeneic hematopoietic cell transplantation","volume":"29","author":"Gjaerde","year":"2023","journal-title":"Transpl Cell Ther"},{"issue":"3","key":"2026032014063830400_bib6","doi-asserted-by":"crossref","first-page":"e89798","DOI":"10.1172\/jci.insight.89798","article-title":"An early-biomarker algorithm predicts lethal graft-versus-host disease and survival","volume":"2","author":"Hartwell","year":"2017","journal-title":"JCI Insight"},{"issue":"3","key":"2026032014063830400_bib7","doi-asserted-by":"crossref","first-page":"S230","DOI":"10.1016\/j.bbmt.2018.12.220","article-title":"Ann Arbor score predicts thrombotic microangiopathy but not graft-versus-host disease in pediatric bone marrow transplant recipients","volume":"25","author":"Sampson","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"issue":"8","key":"2026032014063830400_bib8","first-page":"660.e1-660.e8","article-title":"Elevation of early plasma biomarkers in patients with clinical risk factors predicts increased nonrelapse mortality after allogeneic hematopoietic stem cell transplantation","volume":"27","author":"Hotta","year":"2021","journal-title":"Transpl Cell Ther"},{"key":"2026032014063830400_bib9","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.amjcard.2022.11.036","article-title":"A pilot study on human circulating system indicated that regenerating islet-derived protein 3 gamma (REG3A) is a potential prognostic biomarker for sepsis","volume":"190","author":"Ding","year":"2023","journal-title":"Am J Cardiol"},{"issue":"6","key":"2026032014063830400_bib10","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1056\/NEJMoa1213299","article-title":"ST2 as a marker for risk of therapy-resistant graft-versus-host disease and death","volume":"369","author":"Vander Lugt","year":"2013","journal-title":"N Engl J Med"},{"issue":"9","key":"2026032014063830400_bib11","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1016\/j.bbmt.2015.05.019","article-title":"Establishment of definitions and review process for consistent adjudication of cause-specific mortality after allogeneic unrelated-donor hematopoietic cell transplantation","volume":"21","author":"Hahn","year":"2015","journal-title":"Biol Blood Marrow Transpl"},{"issue":"7","key":"2026032014063830400_bib12","first-page":"688.e1-688.e9","article-title":"Treatment-responsive acute graft-versus-host disease after post-transplantation cyclophosphamide-based prophylaxis: incidence and clinical outcomes","volume":"30","author":"Herzog","year":"2024","journal-title":"Transpl Cell Ther"},{"issue":"10","key":"2026032014063830400_bib13","first-page":"681","article-title":"Characteristics of graft-versus-host disease (GvHD) after post-transplantation cyclophosphamide versus conventional GvHD prophylaxis","volume":"28","author":"Saliba","year":"2022","journal-title":"Transpl Cell Ther"},{"issue":"4","key":"2026032014063830400_bib14","doi-asserted-by":"crossref","first-page":"101111","DOI":"10.1016\/j.beha.2019.101111","article-title":"MAGIC biomarkers of acute graft-versus-host disease: biology and clinical application","volume":"32","author":"Srinagesh","year":"2019","journal-title":"Best Pract Res Clin Haematol"},{"issue":"9","key":"2026032014063830400_bib15","first-page":"798.e1-798.e10","article-title":"Infection-related mortality in adults and children undergoing allogeneic hematopoietic cell transplantation: an Australian registry report","volume":"27","author":"Lindsay","year":"2021","journal-title":"Transpl Cell Ther"},{"issue":"4","key":"2026032014063830400_bib16","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1038\/s41409-020-01092-x","article-title":"Patterns of infection and infectious-related mortality in patients receiving post-transplant high dose cyclophosphamide as graft-versus-host-disease prophylaxis: impact of HLA donor matching","volume":"56","author":"Irene","year":"2021","journal-title":"Bone Marrow Transpl"},{"issue":"5","key":"2026032014063830400_bib17","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1182\/bloodadvances.2021004319","article-title":"The simplified comorbidity index: a new tool for prediction of nonrelapse mortality in allo-HCT","volume":"6","author":"Shouval","year":"2022","journal-title":"Blood Adv"},{"issue":"8","key":"2026032014063830400_bib18","doi-asserted-by":"crossref","first-page":"2912","DOI":"10.1182\/blood-2005-05-2004","article-title":"Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT","volume":"106","author":"Sorror","year":"2005","journal-title":"Blood"},{"issue":"20","key":"2026032014063830400_bib19","doi-asserted-by":"crossref","first-page":"4715","DOI":"10.1002\/cncr.24531","article-title":"Risk score for outcome after allogeneic hematopoietic stem cell transplantation: a retrospective analysis","volume":"115","author":"Gratwohl","year":"2009","journal-title":"Cancer"},{"issue":"9","key":"2026032014063830400_bib20","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1182\/blood.2024025106","article-title":"Novel MAGIC composite scores using both clinical symptoms and biomarkers best predict treatment outcomes of acute GVHD","volume":"144","author":"Akahoshi","year":"2024","journal-title":"Blood"},{"issue":"1","key":"2026032014063830400_bib21","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1182\/bloodadvances.2022008073","article-title":"Interventions to reduce infections in patients with hematological malignancies: a systematic review and meta-analysis","volume":"7","author":"Chai","year":"2023","journal-title":"Blood Adv"},{"issue":"1","key":"2026032014063830400_bib22","first-page":"44","article-title":"A controlled trial of long-term administration of intravenous immunoglobulin to prevent late infection and chronic graft-vs.-host disease after marrow transplantation: clinical outcome and effect on subsequent immune recovery","volume":"2","author":"Sullivan","year":"1996","journal-title":"Biol Blood Marrow Transpl"},{"issue":"1","key":"2026032014063830400_bib23","doi-asserted-by":"crossref","first-page":"8","DOI":"10.7326\/0003-4819-139-1-200307010-00007","article-title":"Should immunoglobulin therapy be used in allogeneic stem-cell transplantation? A randomized, double-blind, dose effect, placebo-controlled, multicenter trial","volume":"139","author":"Cordonnier","year":"2003","journal-title":"Ann Intern Med"},{"issue":"1","key":"2026032014063830400_bib24","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.jinf.2017.10.009","article-title":"Fluoroquinolone prophylaxis in haematological cancer patients with neutropenia: ECIL critical appraisal of previous guidelines","volume":"76","author":"Mikulska","year":"2018","journal-title":"J Infect"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/6\/2054\/2509476\/blooda_adv-2025-017621-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/6\/2054\/2509476\/blooda_adv-2025-017621-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T18:06:48Z","timestamp":1774030008000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/10\/6\/2054\/566014\/A-biomarker-risk-assessment-tool-predicts"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,16]]},"references-count":24,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,3,24]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2025017621","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,3,24]]},"published":{"date-parts":[[2026,3,16]]}}}